ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, J. J.
Right arrow Articles by Cohn, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, J. J.
Right arrow Articles by Cohn, L. H.

The Annals of Thoracic Surgery, Vol 41, 419-424, Copyright © 1986 by The Society of Thoracic Surgeons


ARTICLES

Hemodynamic, metabolic, and morphological effects of cardiopulmonary bypass with a fluorocarbon priming solution

JJ Stone, W Piccione Jr, LD Berrizbeitia, GR Dance, FJ Schoen, RJ Shemin and LH Cohn

Systemic perfusion, myocardial contractility, and morphological changes during and after cardiopulmonary bypass (CPB) were investigated in 22 greyhounds; Fluosol-DA 20% (FDA) and normal saline (NaCl) were compared as priming solutions for hypothermic (25 degrees C) CPB. Hemodynamic and oxygenation indices were similar in all groups. Animals with fluorocarbon primes had higher serum lactate concentrations (mean +/- standard error of the mean [SEM]) during CPB (NaCl 1.64 +/- 0.2, FDA 2.39 +/- 0.3, p less than 0.01), representing an increase over the control of 12% and 319% in the NaCl and FDA groups, respectively. After CPB, serum lactate concentration remained elevated in the FDA group, but it returned to the level of the control in the NaCl group (NaCl 1.49 +/- 0.5, FDA 2.29 +/- 1.1, p less than 0.01); increases over the control level were 7% and 302% in the NaCl and FDA groups, respectively. Myocardial contractility after CPB, expressed as dP/dt[40], was similar in the two experimental groups. Three weeks after CPB, a histological examination by light microscopy of multiple organs obtained from a separate group of 12 animals treated similarly was performed, demonstrating no significant morphological differences between animals primed with fluorocarbon or with saline. The results suggest that FDA is a satisfactory priming agent for hypothermic CPB. It adequately preserves myocardial function and causes no adverse morphological changes, but a persistent, as yet unexplained, elevation in serum lactate concentration occurs.


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
T. Gardeazabal, M. Cabrera, P. Cabrales, M. Intaglietta, and J. C. Briceno
Oxygen transport during hemodilution with a perfluorocarbon-based oxygen carrier: effect of altitude and hyperoxia
J Appl Physiol, August 1, 2008; 105(2): 588 - 594.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1986 by The Society of Thoracic Surgeons.